Shareholders have to seriously question the competency of Peter Cook as a CEO. In the first instant, BTA had to be dragged by the ASX query to announce the numerous worthy news to the public. And even then, the worthy news is announced in the most negative manner.
Quote: "On 13 March 2012, BioCryst Pharmaceuticals, Inc (BioCryst) in its public Securities and Exchange Commission (SEC) filing indicated that it would seek to correct an apparent error by the United States Patent and Trademark Office (USPTO) in its granting of a patent to Biota covering certain Hepatitis C antivirals to which BioCryst claim priority. The matter appears to be an issue between BioCryst and USPTO however Biota confirms the granting of the patent by the USPTO in February 2012. ".
AN APPARENT ERROR!! Did Peter Cook not agreed it is an apparent error? Is it coincidental that The lower the BTA share price is in June, the more free oopies Peter Cook gets?
It is announced as if the patent matter is an issue between Biocryst and UPTSO - really? Is it implied that it is of no concern or of interest to Biota?
The procedure for Biota's patent application involves:
1) Biota filing the patent application
2) UPTSO examines and then publishes the patent application
to the public.
3) Any party may object to the patent application and in this specific case, BCRX would have filed an objection.
4) UPTSO then examines the materials before it (application and the objections) and if necessary carry out additional investigation and then announce the acceptance or rejection of the patent application.
5) Other parties including BCRX may then appeal the matter for judicial review. The judicial process allow parties such as BTA to be present. Thus to state that the matter is an issue between Biocryst and UPTSO is in my opinion a clear understatement downplaying the importance of the award of the patent to BTA.
Add to My Watchlist
What is My Watchlist?